Markets · 1 sources covering this

Zydus hits 52-week high, can the optimism continue?

Zydus Lifesciences has gained 32% in 2026, helped by favourable US FDA inspections, resilient India growth and a strong pipeline, but US weakness and margin pressure remain key risks.

Share:WhatsApp X Reddit Facebook LinkedIn

Coverage spectrum

0 L · 0 C · 1 R

How 1 sources are covering this

MintLean R·1h ago
Zydus hits 52-week high, can the optimism continue?
Zydus Lifesciences has gained 32% in 2026, helped by favourable US FDA inspections, resilient India growth and a strong pipeline, but US weakness and margin pressure remain key risks.
Read at Mint →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://hindustansphere.com/embed/cluster/0ce57a90492448db288251973bb41c8fd1286327"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Zydus hits 52-week high, can the optimism continue?"></iframe>

Zydus hits 52-week high, can the optimism continue?

How 1 sources are covering this

Zydus hits 52-week high, can the optimism continue?

More from Markets

US bond market: Why is AI blowout holds key for the Indian stock market?

Global Market: Eurozone bond selloff pauses, yields stay near multi-year highs

Money doubled: Milky Mist, Technocraft, Xtranet, IndoMIM, ESDS turn IPO multibaggers - What’s special? Pattern decoded

Penny stock under 10 rupees jumps 5% despite weak trends on Dalal Street; here's latest company update

Reader

Trust & legal

Across the network